IRIC’s medicinal chemistry core facility involved in the first project with Bristol-Myers Squibb and colleagues from Bristol-Myers Squibb, NJ.

Université de Montréal (UdeM) and the Institute for Research in Immunology and Cancer – Commercialization of Research (IRICoR) today announced that researchers from UdeM’s Institute for Research in Immunology and Cancer (IRIC) and Bristol-Myers Squibb Company have jointly identified a small molecule drug candidate against a novel target. This achievement represents a major pre-clinical milestone in the research collaboration between UdeM, IRICoR and Bristol-Myers Squibb and triggers a milestone payment to UdeM.

The UdeM and IRICoR medicinal chemistry component of this collaboration was carried out in IRIC’s medicinal chemistry core facility. This facility employs 20 industry-trained chemists who are supported by 5 biologists and other professionals who are actively working on a number of innovative drug discovery projects being funded by IRICoR.

“We are very pleased that our medicinal chemistry team achieved this very important milestone. The clinical candidate molecule that was identified in close collaboration with Bristol-Myers Squibb meets very stringent criteria,” commented Dr. Anne Marinier, Director of IRIC’s Medicinal Chemistry Core Facility at UdeM. “This speaks to the talent of our team and our ability to deliver high-quality, optimized small molecules based on a seamless integration of biology and medicinal chemistry groups under a same roof’.”

“This milestone in our long-standing collaboration with Bristol-Myers Squibb, and its associated payment, further validates IRICoR’s business model of working closely with leading pharmaceutical companies to identify clinical candidate molecules,” explains Dr. Michel Bouvier, President and CEO of IRICoR.

About  UdeM | Université de Montréal

Deeply rooted in Montreal and dedicated to its international mission, the Université de Montréal is one of the top universities in the French-speaking world. Founded in 1878, the Université de Montréal today has 15 faculties and together with its two affiliated schools, HEC Montréal and École Polytechnique, constitutes the largest centre of higher education and research in Québec and one of the major centres in North America. It brings together 2,500 professors and researchers, accommodates more than 60,000 students. For more information, please visit www.umontreal.ca.

About IRIC | Institute for Research in Immunology and Cancer

An ultra-modern research hub and training centre located in the heart of Université de Montréal, the Institute for Research in Immunology and Cancer (IRIC) was created in 2003 to shed light on the mechanisms of cancer and discover new, more effective therapies to counter this plague. IRIC operates according to a model that is unique in Canada. Its innovative approach to research has already led to discoveries that will, over the coming years, have a significant impact on the fight against cancer. For more information about IRIC, please visit www.iric.ca.

About IRICoR | Institute for Research in Immunology and Cancer – Commercialization of Research

IRICoR is a non-profit organization whose mandate is to accelerate the discovery, development and commercialization of novel drugs that originate from Université de Montréal. IRICoR, as a Center of Excellence in Commercialization and Research, invests in highly innovative projects to rapidly transition them from academia to the market, while identifying the best development partners for these commercially-promising projects. For more information about IRICoR, please visit www.iricor.ca.

For more information:

Steven J. Klein, Ph.D., MBA
Vice-President, Business Development
IRICoR | Institute for Research in Immunology and Cancer – Commercialization of Research
Telephone: 514-343-6647
Email: steven.klein@iricor.ca

Gilles Noël, Ph.D.
Director, Research and Technology Transfer
UdeM | Université de Montréal
Telephone: 514-343-2307
Email: gilles.noel@umontreal.ca